A share price of CytomX Therapeutics Inc [CTMX] is currently trading at $2.31, up 4.52%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CTMX shares have gain 9.48% over the last week, with a monthly amount glided 8.71%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CytomX Therapeutics Inc [NASDAQ: CTMX] stock has seen the most recent analyst activity on May 15, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $5 for it. On May 28, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $3.50 on the stock. Wedbush upgraded its rating to a Outperform but stick to its price target of $8 on May 09, 2024. Jefferies upgraded its rating to a Buy and raised its price target to $8 on May 06, 2024. JP Morgan upgraded its rating to Neutral for this stock on April 22, 2024. In a note dated November 14, 2022, BMO Capital Markets downgraded an Market Perform rating on this stock and revised its target price from $3 to $2.60.
CytomX Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.40 and $3.10. Currently, Wall Street analysts expect the stock to reach $5.73 within the next 12 months. CytomX Therapeutics Inc [NASDAQ: CTMX] shares were valued at $2.31 at the most recent close of the market. An investor can expect a potential return of 148.05% based on the average CTMX price forecast.
Analyzing the CTMX fundamentals
Trailing Twelve Months sales for CytomX Therapeutics Inc [NASDAQ:CTMX] were 147.56M which represents 22.80% growth. Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.28%. To continue investigating profitability, this company’s Return on Assets is posted at 0.42, Equity is -5.53 and Total Capital is 0.74. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.20 points at the first support level, and at 2.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.41, and for the 2nd resistance point, it is at 2.51.
Ratios To Look Out For
To put it in perspective, the Current Ratio for CytomX Therapeutics Inc [NASDAQ:CTMX] is 1.73. In addition, the Quick Ratio stands at 1.73 and the Cash Ratio stands at 0.95. Considering the valuation of this stock, the price to sales ratio is 2.47, the price to book ratio is 7.43 and price to earnings (TTM) ratio is 4.66.
Transactions by insiders
Recent insider trading involved Ogden Christopher, Chief Financial Officer, that happened on Jun 16 ’25 when 10614.0 shares were sold. Chief Financial Officer, Ogden Christopher completed a deal on Jun 13 ’25 to sell 1641.0 shares. Meanwhile, SVP, Chief Scientific Officer BELVIN MARCIA sold 13884.0 shares on Jun 16 ’25.
